Medicare's new GLP-1 Bridge program will let eligible beneficiaries pay $50 a month for weight-loss drugs such as Wegovy or Zepbound, a fraction of retail prices that often run $150 to $300 or more. The pilot, run by the Centers for Medicare & Medicaid Services, opens July 1 and closes December 31, 2027, marking the first time Medicare has subsidized GLP-1s explicitly for obesity rather than diabetes or cardiovascular disease.

An elderly patient fills out a prior authorization form at a doctor's office reception desk.

A Coverage Gap Nearly Two Decades in the Making

Medicare has historically excluded drugs prescribed solely for weight loss, a policy that predates the GLP-1 boom by decades. Beneficiaries could only get coverage for semaglutide or tirzepatide products if they had type 2 diabetes, established cardiovascular disease, moderate to severe sleep apnea, or fatty liver disease. That left a large population of seniors with obesity but without a qualifying comorbidity paying full freight, often several hundred dollars monthly, indefinitely.

The Bridge program does not rewrite that underlying statute. Instead it operates as a demonstration outside standard Medicare Part D structures, meaning the $50 copay sits apart from annual deductibles, out-of-pocket caps, the Medicare Prescription Payment Plan, and low-income subsidy calculations. Every participant pays the same flat $50 regardless of income, which simplifies administration but also means the program doesn't layer additional assistance for beneficiaries who might otherwise qualify for subsidized Part D costs.

KFF, the health policy research organization, estimates roughly 3.8 million Medicare beneficiaries could be eligible based on 2023 data. Chris Klomp, director of Medicare and chief counselor at the Department of Health and Human Services, has offered a more conservative near-term estimate of

A Coverage Gap Nearly Two Decades in the Making

More to read